Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05528939 · ClinicalTrials.gov registry record · NA

Feasibility/Acceptability of Attentional-Control Training in Survivors

A NA study of Pediatric Cancer and Pediatric ALL, sponsored by Children's National Research Institute.

Recruiting
Registry status
NA
Development phase
50
Enrollment target
1
Study location

NCT05528939 is a NA study of Pediatric Cancer and Pediatric ALL that is actively recruiting participants, run by Children's National Research Institute. The registered enrollment target is 50 participants, below the 1,490-participant average among 51 other Pediatric Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05528939, a NA study of Pediatric Cancer and Pediatric ALL, is actively recruiting participants, sponsored by Children's National Research Institute.

RECRUITING
Registry status
NA
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

This is a multicenter pilot randomized controlled trial, with an active control condition, of the feasibility, acceptability, and preliminary efficacy of EndeavorRx in a cohort of survivors of acute lymphoblastic leukemia or brain tumor ages 8-16 who are \> 1 year from the end of therapy.

Interventions

  • DEVICE EndeavorRx
  • OTHER Control video game

Study Locations (1)

District of Columbia

  • Children's National Hospital - Washington D.C.

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2023-06-14
Est. Completion 2025-08-31
Phase NA

What the Registry Record Tells You About NCT05528939

The ClinicalTrials.gov registry entry for NCT05528939 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,490-participant average among 51 other Pediatric Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Children's National Research Institute, which has 92 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Pediatric Cancer appearing as the primary indexed condition, and to 2 interventions - of which EndeavorRx is the first listed.

NCT05528939 reports 1 study location spanning 1 distinct geographic area - top geographies include District of Columbia.

Frequently Asked Questions

What is clinical trial NCT05528939 about?

NCT05528939 is a clinical study titled "Feasibility/Acceptability of Attentional-Control Training in Survivors". This is a multicenter pilot randomized controlled trial, with an active control condition, of the feasibility, acceptability, and preliminary efficacy of EndeavorRx in a cohort of survivors of acute lymphoblastic leukemia or brain tumor ages 8-16 who are \> 1 year from the end of therapy.

What is the current status of trial NCT05528939?

This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2023-06-14. Estimated completion is 2025-08-31.

What conditions does trial NCT05528939 study?

This clinical trial studies the following conditions: Pediatric Cancer, Pediatric ALL, Pediatric Brain Tumor, Attention Difficulties, Cognitive Deficit in Attention.

What interventions are being tested in trial NCT05528939?

The interventions under investigation include: EndeavorRx (DEVICE), Control video game (OTHER).

Who is sponsoring clinical trial NCT05528939?

This trial is sponsored by Children's National Research Institute, which has 92 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05528939 being conducted?

This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pediatric Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.